CervoMed Inc. (CRVO)

In the past six months, CervoMed Inc.'s stock price has been impacted by several events, including the release of Q4 results featuring advancements in the neflamapimod program for DLB, positive Phase 2b RewinD-LB clinical data presented at CTAD 2025, and alignment with the FDA and global regulators for its planned Phase 3 trial design. The company also reported its third-quarter 2025 financial results and provided corporate updates, including an alignment with the FDA on key aspects of its planned Phase 3 clinical trial in DLB. The stock price has been volatile, underperforming both the US Biotechs industry and the broader US Market over the past year. As of April 1, 2026, the stock price was $3.85, with a 52-week high of $14.00 and a low of $3.51.

The provided information does not indicate any specific demand seasonality for CervoMed Inc.'s products and services. Demand for neflamapimod is likely driven by disease prevalence and clinical trial outcomes rather than seasonal factors.

CervoMed Inc. is a clinical-stage biotechnology company focused on developing treatments for age-related neurological disorders, operating within the Healthcare sector, specifically in the Biotechnology & Drugs industry. Their lead product candidate, neflamapimod, is an orally administered small molecule brain penetrant that inhibits p38α, potentially reversing synaptic dysfunction and improving neuron health. Neflamapimod is in clinical development for indications like dementia with Lewy bodies (DLB), Alzheimer's Disease (AD), and frontotemporal dementia (FTD). The company is currently evaluating neflamapimod in its RewinD-LB Trial and plans to initiate a global Phase 3 trial in the second half of 2026. CervoMed also has EIP200 in preclinical trials.

CervoMed Inc. is headquartered in Boston, Massachusetts, United States, and conducts its clinical trials primarily in the United States.

The provided search results do not contain specific information regarding CervoMed Inc.'s brand reputation in the past year or any events that have specifically affected its reputation. However, the company has received a consensus rating of "Moderate Buy" from analysts, with an average rating score of 2.63. CervoMed scored higher than 84% of companies evaluated by MarketBeat and ranked 87th out of 852 stocks in the medical sector.

The initial search results did not provide specific details on major institutional and individual owners of CervoMed Inc.